Cyclodextrin-Modified Agents Bioavailability Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for manufacturing cyclodextrin complexes for active agents are not optimized, leading to limited clinical potential due to generic approaches, resulting in undesirable bioavailability and stability issues.
Innovation Solution
The method involves optimizing cyclodextrin complex production by using clinically relevant biological assays to vary manufacturing parameters, such as temperature, pressure, and molar ratios, to enhance bioavailability and stability, specifically incorporating cyclodextrins like beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin, and gamma-cyclodextrin with agents like curcumin and rutin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If generic methods are used to manufacture cyclodextrin complexes, then manufacturing simplicity is maintained, but bioavailability and clinical activity are limited
Solution Approach 1:
The patent applies parameter changes by systematically varying manufacturing parameters including temperature (e.g., 25°C, 37°C, 50°C), pressure (atmospheric to elevated), molar ratios of cyclodextrin to active agent (e.g., 1:1, 2:1, 3:1), and reaction time to optimize complex formation. This resolves the contradiction by transforming a generic process into a parameter-optimized process that achieves high bioavailability while maintaining manufacturing feasibility through controlled variable changes.
Solution Approach 2:
The patent implements dynamics by transitioning from static generic manufacturing conditions to dynamic optimized conditions where parameters are actively adjusted based on the specific active agent and desired clinical outcome. The manufacturing process becomes adaptable, allowing optimization for different agents (e.g., curcumin, rutin) while maintaining a systematic approach that balances complexity with effectiveness.
2Reliability
If established generic methods are employed, then ease of manufacture is maintained, but clinical potential is limited
Solution Approach 1:
The patent resolves this contradiction by changing physical and chemical parameters of the manufacturing process, including using specific temperature ranges (e.g., 37°C for physiological relevance), controlled molar ratios (e.g., 2:1 cyclodextrin to agent), and optimized reaction times. These parameter changes enhance stability and clinical potential while keeping the manufacturing process systematic and manageable through defined parameters rather than uncontrolled generic conditions.
3Reliability
If non-optimized manufacturing parameters are used, then process simplicity is maintained, but clinical activity is reduced
Solution Approach 1:
The patent systematically changes manufacturing parameters including temperature (25°C, 37°C, 50°C), pressure (atmospheric to elevated), molar ratios (1:1, 2:1, 3:1 cyclodextrin to agent), and reaction time to optimize clinical activity. This resolves the contradiction by providing a structured parameter optimization framework that enhances clinical activity while maintaining process manageability through defined variables and systematic variation.
Solution Approach 2:
The patent implements feedback mechanisms by using biological assays to evaluate the clinical activity of manufactured cyclodextrin complexes and using this information to refine and optimize manufacturing parameters. This feedback loop allows continuous improvement of clinical activity while systematically managing the complexity of the optimization process through data-driven parameter adjustment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This optimized approach significantly improves the clinical activity of cyclodextrin-modified agents, demonstrating higher efficacy compared to traditional methods, with enhanced bioavailability and stability, as shown in preclinical models for diabetes and COVID-19 treatments.
Implementation Method 1
Cyclodextrins are a family of cyclic oligosaccharides that possess a hydrophilic outer surface and a lipophilic central cavity or pocket. In the present method, a substance becomes bound, entrapped, and/or complexed within the central pocket of the cyclodextrin, and such binding increases the water solubility and stability of the substance.
Data Source
AI summary
Compositions and methods are disclosed for enhancing the bioavailability and/or increasing the stability of at least one agent by modifying the at least one agent with cyclodextrin. Pharmaceutical compositions including the cyclodextrin-modified agents are disclosed. Methods of manufacturing the cyclodextrin-modified agents as well as methods of using the cyclodextrin-modified agents are also disclosed.